✦ LIBER ✦

A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

✍ Scribed by Laura Q. M. Chow; S. Gail Eckhardt; Cindy L. O’Bryant; Mary Kay Schultz; Mark Morrow; Stacy Grolnic; Michele Basche; Lia Gore

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I and pharmacokinetic study of lon

✍ Carlos Castaneda; Kellen L. Meadows; Roxanne Truax; Michael A. Morse; Scott H. K 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 358 KB

A phase I and pharmacologic study of the

✍ A. S. T. Planting; P. Sonneveld; A. van der Gaast; A. Sparreboom; M. E. L. van d 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 253 KB

A phase I and pharmacologic study of the

✍ André Planting; Ate van der Gaast; Patrick Schöffski; Michele Bartkowski; Coleta 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 219 KB

A phase I study of the safety and pharma

✍ Herbert I. Hurwitz; Roger B. Cohen; J. Patrick McGovren; Samit Hirawat; William 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 308 KB

A Phase I study to assess the safety, to

✍ J. R. Infante; R. Kurzrock; J. Spratlin; H. A. Burris; S. G. Eckhardt; J. Li; K. 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 338 KB

A phase I and pharmacologic study of the

✍ E. Claire Dees; Bert H. O’Neil; Celeste M. Lindley; Frances Collichio; Lisa A. C 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 527 KB